Thrivent Financial for Lutherans Lowers Holdings in Enanta Pharmaceuticals, Inc. $ENTA

Thrivent Financial for Lutherans lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 60.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 34,041 shares of the biotechnology company’s stock after selling 51,793 shares during the period. Thrivent Financial for Lutherans owned about 0.16% of Enanta Pharmaceuticals worth $407,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in ENTA. AlphaQuest LLC increased its position in Enanta Pharmaceuticals by 18.1% during the 3rd quarter. AlphaQuest LLC now owns 10,198 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 1,562 shares during the period. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth approximately $226,000. Bridgeway Capital Management LLC lifted its position in shares of Enanta Pharmaceuticals by 50.8% in the 2nd quarter. Bridgeway Capital Management LLC now owns 29,700 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 10,000 shares during the period. Marshall Wace LLP increased its holdings in Enanta Pharmaceuticals by 0.8% during the second quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock valued at $6,482,000 after buying an additional 6,522 shares during the period. Finally, Stonepine Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 2.3% during the second quarter. Stonepine Capital Management LLC now owns 604,066 shares of the biotechnology company’s stock valued at $4,567,000 after buying an additional 13,324 shares during the period. 94.99% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ENTA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a report on Wednesday, January 21st. JPMorgan Chase & Co. began coverage on Enanta Pharmaceuticals in a research report on Friday, November 14th. They set an “overweight” rating and a $17.00 price objective on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 10th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $20.33.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, insider Yat Sun Or sold 2,390 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total transaction of $34,009.70. Following the sale, the insider owned 371,392 shares in the company, valued at approximately $5,284,908.16. The trade was a 0.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the transaction, the insider owned 30,620 shares of the company’s stock, valued at approximately $435,722.60. The trade was a 6.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 11,961 shares of company stock worth $170,149 in the last 90 days. Insiders own 11.48% of the company’s stock.

Enanta Pharmaceuticals Stock Up 0.1%

ENTA opened at $13.86 on Wednesday. The company has a market cap of $402.20 million, a P/E ratio of -4.33 and a beta of 0.98. The firm’s 50-day moving average price is $14.07 and its 200-day moving average price is $11.61. Enanta Pharmaceuticals, Inc. has a 52-week low of $4.09 and a 52-week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.12. The company had revenue of $18.62 million for the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. On average, research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.